Our company brochure provides insights into the history, development, current status and future of BeiGene. Discover our global team, currently marketed anti-cancer pharmaceuticals, and extensive oncology pipeline.
BeiGene is a fully-integrated biopharmaceutical company co-founded in 2010 by John Oyler, an American entrepreneur, and Dr. Xiaodong Wang, one of the youngest ever U.S. Academy of Science members and Director of China’s National Institute of Biological Sciences (NIBS) in Beijing. The two set out to build a unique company that was globally focused from its inception, to develop novel cancer therapies where there is global unmet need.
With over 3,800 employees, 10 offices on 4 continents and trials in 35 countries and regions, BeiGene is a well-developed and rapidly expanding global company.
We currently market two internally-discovered oncology products: BTK inhibitor BRUKINSA™ (zanubrutinib) in the U.S., and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma
Cancer has no borders. Neither do we.